Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2010

Open Access 01-12-2010 | Case report

Prozone effect of serum IgE levels in a case of plasma cell leukemia

Authors: Giampaolo Talamo, William Castellani, Nathan G Dolloff

Published in: Journal of Hematology & Oncology | Issue 1/2010

Login to get access

Abstract

We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jako JM, Gesztesi T, Kaszas I: IgE lambda monoclonal gammopathy and amyloidosis. Int Arch Allergy Immunol. 1997, 112: 415-421. 10.1159/000237490.CrossRefPubMed Jako JM, Gesztesi T, Kaszas I: IgE lambda monoclonal gammopathy and amyloidosis. Int Arch Allergy Immunol. 1997, 112: 415-421. 10.1159/000237490.CrossRefPubMed
2.
3.
go back to reference Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF: Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007, 78: 353-357. 10.1111/j.1600-0609.2007.00825.x.CrossRefPubMed Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF: Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007, 78: 353-357. 10.1111/j.1600-0609.2007.00825.x.CrossRefPubMed
4.
go back to reference Chiu W, Pullon H, Woon ST, Oei P, The R, Ameratunga R: IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia. Pathology. 42: 82-84. 10.3109/00313020903434660. Chiu W, Pullon H, Woon ST, Oei P, The R, Ameratunga R: IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia. Pathology. 42: 82-84. 10.3109/00313020903434660.
5.
go back to reference Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G: Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009, 27: 637-638. 10.1200/JCO.2008.20.1491.CrossRefPubMed Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G: Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009, 27: 637-638. 10.1200/JCO.2008.20.1491.CrossRefPubMed
6.
go back to reference Kairemo KJ, Lindberg M, Prytz M: IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999, 59: 451-456. 10.1080/00365519950185472.CrossRefPubMed Kairemo KJ, Lindberg M, Prytz M: IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999, 59: 451-456. 10.1080/00365519950185472.CrossRefPubMed
7.
go back to reference IgE immunoglobulin. Br Med J. 1972, 4: 250-251. 10.1136/bmj.4.5835.250. IgE immunoglobulin. Br Med J. 1972, 4: 250-251. 10.1136/bmj.4.5835.250.
8.
go back to reference Invernizzi F, Monti G, Caviglia AG, Meroni P, Zanussi C: A new case of IgE myeloma. Acta Haematol. 1991, 85: 41-44. 10.1159/000204851.CrossRefPubMed Invernizzi F, Monti G, Caviglia AG, Meroni P, Zanussi C: A new case of IgE myeloma. Acta Haematol. 1991, 85: 41-44. 10.1159/000204851.CrossRefPubMed
9.
go back to reference Alexander RL, Roodman ST, Petruska PJ, Tsai CC, Janney CG: A new case of IgE myeloma. Clin Chem. 1992, 38: 2328-2332.PubMed Alexander RL, Roodman ST, Petruska PJ, Tsai CC, Janney CG: A new case of IgE myeloma. Clin Chem. 1992, 38: 2328-2332.PubMed
10.
go back to reference Hegewisch S, Mainzer K, Braumann D: IgE myelomatosis. Presentation of a new case and summary of literature. Blut. 1987, 55: 55-60. 10.1007/BF00319644.CrossRefPubMed Hegewisch S, Mainzer K, Braumann D: IgE myelomatosis. Presentation of a new case and summary of literature. Blut. 1987, 55: 55-60. 10.1007/BF00319644.CrossRefPubMed
11.
go back to reference Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007, 138: 176-185. 10.1111/j.1365-2141.2007.06639.x.CrossRefPubMed Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G: Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007, 138: 176-185. 10.1111/j.1365-2141.2007.06639.x.CrossRefPubMed
12.
go back to reference Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Nakagawa M: IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha. Am J Hematol. 1994, 45: 262-264. 10.1002/ajh.2830450315.CrossRefPubMed Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Nakagawa M: IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha. Am J Hematol. 1994, 45: 262-264. 10.1002/ajh.2830450315.CrossRefPubMed
13.
go back to reference Takemura Y, Ikeda M, Kobayashi K, Nakazawa Y, Mori Y, Mitsuishi T, Ishigame H, Kameko F, Fujita K, Ichinohasama R: Plasma cell leukemia producing monoclonal immunoglobulin E. Int J Hematol. 2009, 90: 402-406. 10.1007/s12185-009-0407-1.CrossRefPubMed Takemura Y, Ikeda M, Kobayashi K, Nakazawa Y, Mori Y, Mitsuishi T, Ishigame H, Kameko F, Fujita K, Ichinohasama R: Plasma cell leukemia producing monoclonal immunoglobulin E. Int J Hematol. 2009, 90: 402-406. 10.1007/s12185-009-0407-1.CrossRefPubMed
14.
go back to reference Jimenez-Zepeda VH, Dominguez-Martinez VJ: Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol. 2009, 89: 259-268. 10.1007/s12185-009-0288-3.CrossRefPubMed Jimenez-Zepeda VH, Dominguez-Martinez VJ: Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol. 2009, 89: 259-268. 10.1007/s12185-009-0288-3.CrossRefPubMed
15.
go back to reference Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R: Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003, 101: 1570-1571. 10.1182/blood-2002-08-2436.CrossRefPubMed Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R: Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003, 101: 1570-1571. 10.1182/blood-2002-08-2436.CrossRefPubMed
16.
17.
go back to reference Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, Francia R, Squame E, de Martinis F, Pinto A: Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007, 48: 723-730. 10.1080/10428190601183710.CrossRefPubMed Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, Francia R, Squame E, de Martinis F, Pinto A: Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007, 48: 723-730. 10.1080/10428190601183710.CrossRefPubMed
18.
go back to reference Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009, 23: 215-224. 10.1038/leu.2008.307.CrossRefPubMed Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009, 23: 215-224. 10.1038/leu.2008.307.CrossRefPubMed
19.
go back to reference Butch AW: Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem. 2000, 46: 1719-1721.PubMed Butch AW: Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem. 2000, 46: 1719-1721.PubMed
20.
go back to reference Costa FP, Dourado DA, Borsoi CS, Deeke CD, Valvasori M, Colella R: Transfusion medicine illustrated. Hyperviscosity and the prozone effect in multiple myeloma. Transfusion. 2008, 48: 2056-10.1111/j.1537-2995.2008.01821.x.CrossRefPubMed Costa FP, Dourado DA, Borsoi CS, Deeke CD, Valvasori M, Colella R: Transfusion medicine illustrated. Hyperviscosity and the prozone effect in multiple myeloma. Transfusion. 2008, 48: 2056-10.1111/j.1537-2995.2008.01821.x.CrossRefPubMed
Metadata
Title
Prozone effect of serum IgE levels in a case of plasma cell leukemia
Authors
Giampaolo Talamo
William Castellani
Nathan G Dolloff
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-3-32

Other articles of this Issue 1/2010

Journal of Hematology & Oncology 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine